MedTrace Logo

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2022-12-29

Study results available
· View outcomes & findings →

Summary

This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration will be two weeks. After recruiting CKD participants the investigator will recruit controls with normal kidney function that will receive only ticagrelor and aspirin for two weeks.

Conditions

Interventions

DRUG

Ticagrelor 90mg

Ticagrelor Pill

DRUG

Clopidogrel 75mg

Clopidogrel Pill and a matching placebo to conceal frequency

DRUG

Aspirin 81 mg

Aspirin Pill

Sponsors & Collaborators

  • American Society of Nephrology

    collaborator OTHER

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Jain Nishank, MD · University of Arkansas for Medical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
91 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2021-09-02
Completion
2021-09-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649711 on ClinicalTrials.gov